Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

计划入组 374 人 · 首次发布于 2015 年 1 月 9 日

ATI HVTN804/HPTN095

计划入组 0 人

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

计划入组 35 人 · 首次发布于 2023 年 8 月 23 日

IkT-052

SIT-052

PRA-052

ATI Physical Therapy

United States

Altai Resources Inc

Rosalind Franklin University of Medicine & Science

United States

Aclaris Therapeutics Reports Positive Phase 1a Results for Bispecific Antibody ATI-052, Accelerating Development Timeline

NIDA Funds Small Businesses to Develop Decentralized Clinical Trial Tools for Substance Use Disorders

Appili Therapeutics Advances ATI-1801 Development for Cutaneous Leishmaniasis with FDA Alignment